| Trial ID # | NCT03875820; FRAME |
| Phase | I |
| Drug Class | Signaling Pathway Inhibitors: Integrins-FAK/FAK |
| Drug Name | Defactinib |
| Alternate Drug Names | VS-6063, PF-04554878 |
| Drugs in Trial | Defactinib, Avutometinib |
| Eligible Participant | Recurrent low grade serous ovarian cancer |
| Patients Enrolled | 25, median 4 prior therapies (1-9) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, PFS, evaluated per RECIST |
| Efficacy | RP2D [3.2 mg VS-6766 (2x/week)+200 mg defactinib (BID) q3/4 weeks] ORR: 46% (n=24) |
| Conclusion | VS-6766 (CH5127677)+defactinib shows promising clinical activity in patients with low grade serous ovarian cancer including those who have been previously treated with a MEK inhibitor |
| Reference | Coma S et al. Synergistic antitumor efficacy of the dual RAF/MEK inhibitor VS-6766 with FAK inhibition for treatment of RAS-dependent solid tumor. Cancer Res (2021) Volume 81, Issue 13 Supplement, abstract 1425 Coma S et al. Poster Banerjee S et al. Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer. Annals of Oncology (2021) 32 (suppl_5): abstract 725MO |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.